Canada · Delayed Price · Currency is CAD Loblaw Companies Earnings Call Transcripts
Fiscal Year 2026
-
Revised summary: The event outlined a strategy to expand discount and pharmacy store networks, accelerate digital and AI-driven growth, and leverage private label and healthcare businesses for sustainable earnings. Financial discipline and strong leadership support 8–10% annual EPS growth while investing in price and innovation.
-
Q2 2026 saw strong revenue and earnings growth, stable margins, and robust performance across food, pharmacy, and e-commerce. The company completed the sale of PC Financial, expanded store count, and raised its share repurchase target, while maintaining a positive outlook for the year.
-
The meeting highlighted strong financial results, dividend growth, and major strategic moves, including a significant real estate acquisition and continued expansion in retail and healthcare. All management proposals passed with overwhelming support, while a shareholder proposal on property controls was rejected. Stakeholders engaged on innovation, customer service, and sustainability.
-
Q1 2026 saw strong revenue, margin, and EPS growth, driven by discount and pharmacy expansion, robust online sales, and disciplined capital allocation. Strategic investments and cost reductions supported performance, while consumer trade-down and GLP-1 genericization remain key watchpoints.
Fiscal Year 2025
-
Q4 and full year 2025 saw strong revenue, EPS, and margin growth, driven by new stores, digital expansion, and operational excellence. 2026 guidance calls for high single-digit EPS growth, continued investment in stores and innovation, and robust capital returns to shareholders.
-
EQB will acquire PC Financial from Loblaw for CAD 800 million, creating a leading digital bank with nearly 3.5 million customers and exclusive access to the PC Optimum loyalty program. The deal is expected to close in the second half of 2026, delivering significant revenue, cost, and funding synergies, and has strong support from both companies’ boards and major shareholders.
-
Revenue grew 4.6% to CAD 19.4B, with adjusted EPS up 11.3% and strong gains in both food and drug retail. Online sales rose 18%, and market share increased in discount and conventional channels. Full-year adjusted EPS growth is now expected in the low double digits.
-
Revenue grew 5.2% to CAD 14.5B, with adjusted EBITDA up 7.4% and EPS up 11.6%. Hard discount and supermarket banners gained share, digital and pharmacy segments performed strongly, and a 4-for-1 stock split was announced. Guidance remains unchanged amid macro uncertainty.
-
The joint AGM highlighted strong financial results, increased dividends, and robust shareholder returns for both companies. Strategic investments in retail, healthcare, and real estate were emphasized, while all director nominees and key resolutions passed with overwhelming support. Shareholder proposals on governance, food waste, and data privacy were discussed but not adopted.
-
Q1 2025 saw 4.1% revenue growth, 9.3% adjusted EPS growth, and stable gross margin, driven by strong food and drug retail performance, new store openings, and digital sales momentum. Tariff and inflation risks are being actively managed, with continued investment in value and growth initiatives.
Fiscal Year 2024
-
Delivered strong 2024 results with revenue of CAD 61B and adjusted EPS up 10.3%. Hard discount and T&T banners led growth, while digital and pharmacy initiatives drove engagement. 2025 guidance calls for high single-digit EPS growth, continued store expansion, and robust capital returns.
-
Q3 2024 saw revenue rise 1.5% to CAD 18.5B and adjusted EBITDA up 7.4%, with strong food and drug retail performance and robust online sales. EPS growth is now expected in the low double digits for 2024, with continued investment in new stores and margin improvements.
-
Revenue rose 1.5% to CAD 13.9B, with adjusted EBITDA up 4.5% and EPS up 10.8%. A one-time CAD 156.5M charge for a bread price-fixing settlement impacted GAAP net earnings. Discount banners and pharmacy clinics drove growth, and gross margin improved 90 bps.